Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce Dr. Moe Afaneh, Pharm D., MBA, NRCC, RNC has identified the first four Cannabis Science Brand products as the newest line of Cannabis Science Brand of Products. Dr. Afaneh expects to have a full report next week with the new product offering launch plan including nationwide manufacturing and distribution.

The Cannabis Science Executive Team is finalizing negotiations for the manufacturing and national distribution or this new product line. The commercialization process is well underway including securing manufacturing partners that have the resources to support our national distribution and retail outlets such as pharmacies through to grocery outlets and other multi-national retail outlets. Negotiations will actively continue when the first prototypes are received by Cannabis Science to be review by various nationwide product distributors eagerly looking to release this new line of Cannabis Science Brand of Products.

This new product launch is the first mandate for our newly appointed Chief Operations Officer Dr. Afaneh. He has made great progress in the short time since he has begun, and is now ahead of schedule for this launch. Dr. Afaneh’s mandate includes improving the overall efficiency and quality of Cannabis Science’s national pharmaceutical operations and penetrating additional national markets with new developed high quality Cannabis Science brand products. Dr. Afaneh and the Cannabis Science team are working to enter the over-the-counter (OTC) market in 2012, with non-psychoactive nutraceuticals, as well as to enter the dispensary market with both psychoactive and non-psychoactive cannabis-based treatments.

Dr. Robert Melamede, President of Cannabis Science stated, “Dr. Moe is ahead of our projections and we are very proud. The retail availability of these products should increase revenue and that’s great for Cannabis Science and our shareholders. I am confident that we will realize our financial plans and goals that should bring Cannabis Science to profitability in 2014. I look forward to using many of these products for myself and my family in the near future.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.